The observation that early-relapse patients had their PARP1 inhibitor repressed suggests that using PARP1 inhibitors could serve as a potential solution to the problem of early relapse of pediatric ALL after patients’ complete remission. Here, PARP1 is linked to acute lymphoblastic leukemia.